Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECTIVENESS OF SLOW-RELEASE LANREOTIDE, A LONG-ACTING SOMATOSTATIN ANALOG, IN THE TREATMENT OF ACROMEGALY
Autore:
CHANG TC; CHANG TJ; CHEN MH; HSIAO YL; TSAI KS;
Indirizzi:
NATL TAIWAN UNIV HOSP,DEPT INTERNAL MED TAIPEI 100 TAIWAN NATL TAIWAN UNIV HOSP,DEPT INTERNAL MED TAIPEI 100 TAIWAN EN CHU KONG HOSP,DEPT INTERNAL MED TAIPEI TAIWAN NATL TAIWAN UNIV HOSP,DEPT CLIN PATHOL TAIPEI 100 TAIWAN
Titolo Testata:
Journal of the Formosan Medical Association
fascicolo: 10, volume: 97, anno: 1998,
pagine: 684 - 689
SICI:
0929-6646(1998)97:10<684:EOSLAL>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
GROWTH-HORMONE; TERM TREATMENT; SMS 201-995; FOLLOW-UP; OCTREOTIDE; SECRETION;
Keywords:
ACROMEGALY; LANREOTIDE; GROWTH HORMONE; INSULIN-LIKE GROWTH FACTOR-I; SOMATOSTATIN; OCTREOTIDE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
22
Recensione:
Indirizzi per estratti:
Citazione:
T.C. Chang et al., "EFFECTIVENESS OF SLOW-RELEASE LANREOTIDE, A LONG-ACTING SOMATOSTATIN ANALOG, IN THE TREATMENT OF ACROMEGALY", Journal of the Formosan Medical Association, 97(10), 1998, pp. 684-689

Abstract

We evaluated the effectiveness of slow-release lanreotide, a long-acting somatostatin analogue, in the treatment of acromegaly. Eleven patients with acromegaly were recruited, six of whom had received long-term treatment with octreotide. Lanreotide 30 mg was administered by intramuscular injection every other week for 24 weeks. The frequency of injection was adjusted as clinically needed after 2 weeks. Clinical effects were evaluated, and symptoms were recorded and scored. Finger circumferences and hand volumes were measured. Serum growth hormone (GH) and insulin-like growth factor-1 (IGF-1) concentrations were determined, and an oral glucose test was done at baseline and after treatment. Symptom scores, circumferences of the fingers, hand volumes, and serum GH and IGF-1 concentrations significantly decreased during treatment. Serum GH concentrations returned to normal in five (46%) of the 11 patients, while serum IGF-1 concentrations returned to normal in three (27%). Glucose intolerance was not significantly improved at the end of treatment. Although the mean serum GH concentration was significantly decreased after treatment, it was still not suppressed by glucose. In conclusion, slow-release lanreotide, given either twice or three timesa month, is effective in controlling acromegalic symptoms as well as GH and IGF-I hypersecretion. The treatment is well tolerated and convenient for patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/11/20 alle ore 02:01:52